文献速递慢性肾脏病

靶向抑制肠道微生物TMAO生成促进CKD表型逆转

Targeted Inhibition of Gut Microbial Trimethylamine N -Oxide Production Fosters Regression of CKD Phenotypes.
PubMed 文献 · J Am Soc Nephrol · 2026-07-10

该研究在CD1小鼠中先通过单侧肾切除加高脂饮食±1%胆碱喂养12周建立CKD模型,随后随机给予肠道微生物TMAO抑制剂氟甲基胆碱(FMC)治疗8周。结果显示FMC几乎完全消除循环TMAO,并显著改善mGFR、肾功能指标、纤维化和尿毒症毒素水平,且肾小管间质纤维化出现41%的逆转。

要点

  • CKD建立后抑制TMAO生成可阻止疾病进展并逆转关键病理特征。
  • FMC治疗使mGFR较第一阶段提高39%,肾小管间质纤维化减少41%。
  • FMC改善蛋白尿、胱抑素C、肌酐及多种尿毒症毒素水平。

核心结论

  • CKD建立后药物靶向抑制肠道微生物TMAO生成可阻止疾病进展并促进关键CKD病理生理特征的逆转。

研究设计与样本

  • CD1小鼠第一阶段随机接受单侧肾切除或假手术,并喂食高脂饮食±1%胆碱补充12周以确认CKD。
  • 第二阶段随机继续相同饮食±氟甲基胆碱(FMC)8周,评估对CKD相关表型的影响。

主要发现

  • 12周后胆碱补充的UNx小鼠循环TMAO水平升高15倍,mGFR降低48%,肾小管间质纤维化增加3.5倍。
  • 第二阶段8周后,未接受FMC的胆碱补充UNx小鼠循环TMAO进一步升高,肾功能和纤维化指标持续恶化。
  • FMC治疗组循环TMAO几乎完全消除,mGFR提高超过50%,肌酐、胱抑素C、假尿苷、尿白蛋白/肌酐比值、肾纤维化指标及多种尿毒症毒素水平改善。
  • FMC治疗组肾小管间质纤维化逆转41%,mGFR较第一阶段提高39%。

临床怎么用

  • 提示靶向肠道微生物TMAO通路可能成为CKD治疗策略,但尚未在人体验证。

局限性

  • 研究仅在小鼠模型中进行,结论能否外推至人类CKD患者尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Inhibition of the gut microbial trimethylamine N -oxide (TMAO) pathway after CKD onset both halted disease progression and reversed pathophysiologic CKD features. Inhibition of TMAO formation in established CKD animals improved kidney function, proteinuria, fibrosis, and uremic toxins. In CKD models, a drug that suppressed gut microbial TMAO production yet remains in the intestinal lumen reversed kidney fibrosis and improved GFR. BACKGROUND: Recent studies demonstrate gut microbial trimethylamine N -oxide (TMAO) is clinically and mechanistically linked to CKD development. Prior studies showed selective targeting of gut microbial TMAO production can prevent CKD initiation. A highly relevant clinical question is whether inhibiting TMAO generation can reverse established kidney dysfunction and fibrosis. METHODS: CD1 mice were first randomized (phase 1) to unilateral nephrectomy (UNx) or sham surgery and fed a high-fat diet ±1% choline supplementation to document CKD through measures of multiple indices of kidney function, tissue remodeling/fibrosis, and uremic toxins. Mice were then randomized (phase 2) to continue the same diet±fluoromethylcholine (FMC), a mechanism-based gut microbial TMAO inhibitor, for 8 additional weeks, and the impact on CKD-related phenotypes was assessed. RESULTS: After 12 weeks, choline-supplemented UNx mice exhibited 15-fold higher circulating TMAO levels. In parallel, multiple kidney dysfunction indices progressed, including 48% reduction in measured GFR (mGFR), elevated cystatin C and creatinine, 3.5-fold greater tubulointerstitial fibrosis, and upregulated profibrotic gene expression. After phase 2 (8 weeks±FMC), choline-supplemented (high-TMAO) UNx mice without FMC showed further elevation of circulating TMAO and multiple indices of progressive kidney function decline and fibrosis. Conversely, FMC-treated animals showed virtual elimination in circulating TMAO and significant improvements in all monitored CKD phenotypes, including >50% higher mGFR, and improved (decreased) creatinine, cystatin C, pseudouridine, urinary albumin/creatinine ratio, kidney fibrosis measures, and many uremic toxin levels ( e.g ., indoxyl sulfate and phenylacetylglycine). Beyond halting progression of kidney functional decline and fibrosis, there was frank regression in tubulointerstitial fibrosis (41% reduction) and significant improvement in mGFR (39% increase, end of phase 2 versus phase 1). CONCLUSIONS: Pharmacologic targeting of gut microbial TMAO production after CKD establishment halted disease progression and promoted regression of key CKD pathophysiologic features.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. DiDonato JA, Weeks TL, Gupta N, et al. Targeted Inhibition of Gut Microbial Trimethylamine N -Oxide Production Fosters Regression of CKD Phenotypes. J Am Soc Nephrol. 2026. PMID: 42430743. doi:10.1681/ASN.0000001171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。